OMGA News and Press, Omega Therapeutics Inc. From 09/06/22

Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire CAMBRIDGE, Mass. , Sept. 6, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company pionee...

Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors PR Newswire Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass. , Sept. 1, 2022 /PRNewswire/ -- Omega Thera...

Omega Therapeutics press release ( NASDAQ: OMGA ): Q2 GAAP EPS of -$0.54 in-line. Revenue of $0.48M beats by $0.43M . As of June 30, 2022, the company had cash, cash equivalents and marketable securities totaling $173.7M. For further details see: Omega Th...

Omega Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire FDA Clearance of IND Application for OTX-2002, the First Ever Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma Received Launc...

Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the f...

Omega Therapeutics ( NASDAQ: OMGA ) on Thursday said the U.S. FDA had cleared its investigational new drug (IND) application to start a phase 1/2 trial of its lead product candidate OTX-2002 for the treatment of a type of liver cancer called hepatocellular carcinoma. T...

Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma PR Newswire Represents First Ever Epigenomic Controller, a New Class of Programmable mRNA Therapeutics, to R...

Gainers: Inspira Technologies ( IINN ) +75% . Resolute Forest Products ( RFP ) +64% . Shattuck Labs ( STTK ) +23% . Omega Therapeutics ( OMGA ) +23% . Evofem Biosciences ( EVFM ) +23% . Zevia ( ZVIA ) +21% . Eos E...

Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress on Gastrointestinal Cancer PR Newswire Treatment with epigenomic con...

Gainers: NeuroSense Therapeutics NRSN +83%. Axsome Therapeutics (AXSM) +37%. Agile Therapeutics (AGRX) +31%. GreenLight Biosciences (GRNA) +26%. Femasys (FEMY) +11%. Losers: GeoVax Labs GOVX -14%. SIGA Technologies (SIGA) -14%. Eargo (EAR) -12%. BioAtla...